Drugs / MazF-T
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01787994 | Dec 2012 → Jul 2017 | HIV infectious disease | University of Pennsylvania | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MazF-T | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01787994 ↗ |
| Modality | Cell therapy | “Autologous CD4+ T cells genetically modified with a retroviral vector expressing the MazF endoribonuclease gene” NCT01787994 ↗ |
| Route | Intravenous | “given via intravenous infusion.” NCT01787994 ↗ |